The PennZone

  • Home
  • Marketing
  • Entertainment
  • Music
  • Non-profit
  • Technology
  • Business
  • Health
  • Education

Utah attempts to legalize placenta cell therapy
The PennZone/10266985

Trending...
  • Omnitronics launches Ecosystem Health Dashboard to enable proactive monitoring across dispatch environments
  • Colonial Nissan Helps Multiple Generations of the Community Find Their Next Vehicle
  • Nola Blue Records Announces New Album from Sherman Holmes
Parent's Guide to Cord Blood Foundation
Exclusive: How a small group of patient advocates and biotech companies tricked the Utah legislature into passing a law which sets a precedent. Utah is now the first state to legalize therapy with stem cells from placenta tissue and cord blood.

BROOKEVILLE, Md. - PennZone -- Exclusive: How a small group of patient advocates and biotech companies tricked the Utah legislature into passing a law which sets a precedent. Utah is now the first state to legalize therapy with stem cells from placenta tissue and cord blood.

Parent's Guide to Cord Blood Foundation is a small non-profit in the biotech space. We are the first to break the story that the Utah state legislature did not realize what they were voting for when they passed Utah S.B. 199.

More on The PennZone
  • Meals on Wheels of the Greater Lehigh Valley Awarded $50,000 Grant from Harry C. Trexler Trust
  • RPR Promotes Emily Line to Chief Strategy Officer and Janine Sieja to Chief Product Officer
  • Kellyn Hosts Fourth Lehigh Valley Lifestyle Medicine Symposium
  • Expanding Beyond Space as New Drone Market Opportunities Accelerate Growth: Ascent Solar Technologies (N A S D A Q: ASTI)
  • Lauren Merrell, Dale Sorensen Real Estate, announces price improvement for an extraordinary island retreat

The FDA still considers unapproved stem cell therapies to be illegal, and when it comes to drug regulations, federal law takes supremacy. This is not the same as states ignoring federal law and legalizing recreational drugs. In the case of stem cell therapy, patients that receive unregulated products with insufficient oversight could suffer serious adverse events. The new law Utah S.B. 199 is going to trigger a showdown between the federal government and Utah. Doctors who administer therapy to patients under the new Utah law could be sued by the Dept. of Justice. At a bare minimum, we are calling for the state of Utah to establish oversight of this arena before patients are hurt.

Contact
Frances Verter, PhD
***@parentsguidecordblood.org


Source: Parent's Guide to Cord Blood Foundation

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Porter's Day Care Opens Doors to Brighter Futures
  • Northeast Airlines and Travel, Inc. Initiates FAA Part 121 Certification for Boeing 737-800 Freighter Cargo Operations
  • RevOtter Names Levi Bilbrey CEO, as Company Expands Fractional CMO, RevOps and Web Design Services
  • The J Wes Project Announces "The Mystery of Love" Documentary
  • Walker's Realty and North Jersey Properties Introduce Extraordinary Luxury Estate for Rent in West Orange, New Jersey
  • Extreme Heat Strains Home Appliances: Appliance EMT Offers "Summer Rescue" Relief
  • Independent West Texas Metal Multi-Instrumentalist & Producer. "MAD CHAD™" Russell Surpasses 1.9 Million Project Interactions Via DFGS Productions
  • No Download Needed: Goosechase Adds Browser Play to Every Experience
  • HER Patio Productions celebrates one-year Anniversary of "Say Grace"
  • Working Musicians Academy Partners with Black Dog Music Partners to Give Musicians Independent, Income-Producing Careers
  • Omnitronics launches Ecosystem Health Dashboard to enable proactive monitoring across dispatch environments
  • New Research Identifies "The Great Junk Transfer": 49% of Americans Would Rather Inherit Nothing Than Sort Through a Relative's Belongings
  • Minus K Technology launches it Educational Giveaway for Universities and Colleges in the USA
  • UK Financial Ltd Verifies Maya Preferred PRA Circulating Supply, Proving Its Eight-Year Promise of Under 1M Tokens After Chainlink Labs Agreement
  • Anamorphic 3D Only Works on Fixed Screens. Loud! OOH Put It on a Moving Ad Van for Flood Re
  • From DJ Booths to Disney: Orlando Author Ryan Tiffin Launches "Chasing Magic"
  • Nola Blue Records Announces New Album from Sherman Holmes
  • FDA Food Recall Notices After Outbreak Linked to 98 Hospitalizations: Practical Tips for Safer Grocery Shopping
  • The 'Tax Squeeze': Betsson's Record Quarter Previews the Economics of Finland's 2027 Casino Market
  • Colonial Nissan Helps Multiple Generations of the Community Find Their Next Vehicle

Popular on PennZone

  • CCHR: Congressional Hearing Revives Lessons from MKULTRA Era – Why Past Psychiatric Human Rights Abuses Demand Vigilance Today
  • Community Partnership Brings Live Theater to 150+ Young People
  • Philadelphia's Own Reverend Jamie Knight Returns with "Award-Winning Love
  • Martin A. Sumichrast Joins Hawkeye Systems, Inc. as Chairman of the Board
  • Pacto Medical Wins Red Dot Design Concept Award 2026 for Slimshot® Compact Prefilled Syringe
  • Only One Flight Stands Between Los Angeles Youth Leaders and a Life-Saving Mission in South Africa
  • Heritage at Manalapan Introduces Luxury Single-Family Homes with Exceptional Value in One of Monmouth County's Most Desirable Locations
  • The J. Wes Project Celebrates 11 Years of Love, Music & Inspiration
  • Philadelphia Community Invited to Unite for Praise-A-Thon Summer Concert Benefiting Cobbs Creek
  • Stepping Off the Grid: Savista Retreat Announces New Experiential Packages in Jaipur for Travellers

Similar on PennZone

  • Boston Industrial Solutions, Inc. Introduces SAP-G70 Primer for bonding silicone to silicone and other materials
  • DARPA Selects NRx Pharmaceuticals Defense Subsidiary for Contract Negotiations on FDA-Authorized SPARC-TMS Clinical Trial Advancing Mental Health Care
  • Pacto Medical Wins Red Dot Design Concept Award 2026 for Slimshot® Compact Prefilled Syringe
  • Roohid Parast, J&J Scientist, Comments on New Psoriasis Biomarker Study
  • Postmortem Pathology Expands Access to Private Autopsy Services in Las Vegas
  • From DECA Finalist to Translational Scientist: Roohid Parast on Business Training in Biopharma
  • Why More Phoenix Families Are Turning to Private Autopsy Services for Answers
  • AI-Powered Neuropsychiatry, FDA Regulatory Momentum, Commercial Ketamine Launch Position NRx Pharmaceuticals for Potential Breakout Growth in 2026
  • Longevityresearch.ca publishes cross-disease causal analysis quantifying endpoint reduction across 27 diseases
  • Record Revenue Growth, AI-Driven Healthcare Innovation, Expanding Proprietary Brand and Targeting $200 Million Revenue By 2029: Cosmos Health Inc
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us